| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | DUPAGE MEDICAL TECHNOLOGY INC | 1316 S RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 4 | NIH | 10/23/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | DUPAGE MEDICAL TECHNOLOGY INC | 1316 S RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL156560 | Developing a new drug for treating myocardial ischemia/reperfusion injury | 000 | 2 | NIH | 9/16/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $582,071 ) |
| | 2023 | 2023 | DUPAGE MEDICAL TECHNOLOGY INC | 1316 S RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 4 | NIH | 8/26/2023 | $582,071 |
|
| Issue Date FY: 2022 ( Subtotal = $1,776,688 ) |
| | 2022 | 2022 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL156560 | Developing a new drug for treating myocardial ischemia/reperfusion injury | 000 | 2 | NIH | 8/18/2022 | $1,141,737 |
| | 2022 | 2022 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL142396 | Targeting integrin outside-in signaling for treating sepsis | 001 | 3 | NIH | 5/20/2022 | $634,951 |
| | 2022 | 2021 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 2 | NIH | 10/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,633,788 ) |
| | 2021 | 2021 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 2 | NIH | 8/4/2021 | $776,915 |
| | 2021 | 2021 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R44HL156560 | Developing a new drug for treating myocardial ischemia/reperfusion injury | 000 | 1 | NIH | 9/20/2021 | $856,873 |
| | 2021 | 2018 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R43HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 1 | NIH | 5/7/2021 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R43HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 1 | NIH | 11/20/2018 | $0 |
| | 2019 | 2018 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R43HL142396 | Targeting integrin outside-in signaling for treating sepsis | 001 | 1 | NIH | 12/17/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $225,000 ) |
| | 2018 | 2018 | DUPAGE MEDICAL TECHNOLOGY, INC. | 1316 RIDGE RD | WILLOWBROOK | IL | 60527-1896 | DUPAGE | USA | R43HL142396 | Targeting integrin outside-in signaling for treating sepsis | 000 | 1 | NIH | 8/22/2018 | $225,000 |
|
|
